(Q38578960)

4 September 2017

Future of combination therapy with dabrafenib and trametinib in metastatic melanoma (English)

1 reference

4 September 2017

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26331795%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Yasaman Zia

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26331795%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Lawrence Chen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26331795%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

language of work or name

English

0 references

publication date

2 September 2015

1 reference

Expert Opinion on Pharmacotherapy

4 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26331795%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26331795%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26331795%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

2257-2263

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26331795%20AND%20SRC:MED&resulttype=core&format=json

Final version of 2009 AJCC melanoma staging and classification

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Pathogenetic Implications of BRAF Mutation Distribution in Stage IV Melanoma Patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

B-Raf and the inhibitors: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Ablation of BRaf impairs neuronal differentiation in the postnatal hippocampus and cerebellum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation-positive solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

What's new in melanoma? Combination!

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Improved overall survival in melanoma with combined dabrafenib and trametinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1085509

10.1517/14656566.2015.1085509

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26331795%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference